A responsive outcome for Parkinson's disease neuroprotection futility studies.
about
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatmentsA pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month resultsCaffeine and progression of Parkinson diseasePhase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD StudyClinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's diseaseDeterminants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.A latent model approach to define event onset time in the presence of measurement error.Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease.The futility study--Progress over the last decade.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humansTargets for neuroprotection in Parkinson's diseaseDesigning clinical trials for dystonia.Milestones in movement disorders clinical trials: advances and landmark studies.The promise of futility trials in neurological diseases.Biomarkers in Parkinson's disease: a funder's perspective.Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.Reply to Drs. Olanow and Rascol.Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study.Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.Quantifying Motor Impairment in Movement Disorders.
P2860
Q26995786-3F1DF5A3-E3B4-4BB7-BBFB-E03371443197Q30407150-DD3827FD-37D0-4AC3-B48D-7A9E6FA7A0B7Q30432945-0FA4BB1E-6779-42E2-A774-9A4F5D5D16A5Q30494108-A6BD4779-1644-416E-93AE-3B63F61D652EQ30577157-1FF7EF18-ABFC-429A-8033-8458271863BAQ33639008-0D4A81F1-EB47-462F-9FB5-313A6DB0D297Q33731897-070CAFFC-E7C8-4A33-B55E-DD1A9FA7FF62Q34301396-3D72DA6F-53E4-4926-A4D3-1FD643351D3FQ34373748-2A4FE95E-59AA-4E22-ABD5-11A11F84CE5BQ35048310-6DECE846-F0D1-4A66-89B4-9847954EB34CQ36264697-302D22F2-F3A9-4B07-9A47-1D159FEE1EE5Q36499640-0004900C-AA6D-486C-91F0-3A44AE5E669EQ37062111-A92AFA13-810D-4C22-8EB0-E1656F927B42Q37131239-ADCF6F7E-318F-4873-96F9-9459A6604594Q37161380-B439A04D-54CA-4EA0-9FB8-AE077BE99EECQ37302453-16241844-2B8C-4DCF-A841-B15098C02202Q37506514-CC1DBD44-1B79-4BE8-B3DF-9488A7BA2014Q37882584-4B58B6FC-FF8D-4068-958E-B54C4956190EQ38380170-3453D9E8-FA78-4977-9E2E-201B7AB3BC31Q39827858-05BB23D8-FD19-476A-88BC-A36DC4E28930Q40027470-74EFC8C9-57B7-4508-8D5F-BF1FC861BCEDQ40405786-88C5986D-F16D-4A72-BD0E-D00723A61AFCQ40494176-9251A045-9B13-4670-8855-B17E5F869E56Q47352832-E0AB4B91-D738-4D7B-865C-534807EDA558Q51759987-42CABE26-ECA2-4E51-A76C-878D9ABE954FQ55244629-8DC7EC33-08EA-4AF8-9894-EEA5611B56E5
P2860
A responsive outcome for Parkinson's disease neuroprotection futility studies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@en
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@nl
type
label
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@en
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@nl
prefLabel
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@en
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@nl
P2093
P50
P356
P1433
P1476
A responsive outcome for Parkinson's disease neuroprotection futility studies.
@en
P2093
Barbara C Tilley
Bernard Ravina
Cornelia Kamp
George Fredrick Wooten
Jordan J Elm
Kathleen Shannon
NET-PD Investigators
Paulo Guimaraes
Peng Huang
Yuko Y Palesch
P2860
P304
P356
10.1002/ANA.20361
P577
2005-02-01T00:00:00Z